US Resumption of Ponatinib Marketing for CML

FDA Updates published on December 20, 2013
US Resumption of Ponatinib Marketing for CML
Ponatinib has been reinstated by the US FDA with update to the labeling and a REMS program.
Read More Here U.S. Resumption of Marketing and Commercial Distribution of Ponatinib in Refractory Philadelphia-Positive Leukemias
Last modified: December 23, 2013